Since August 2016, cannabis products and pure cannabis flowers with a THC content of less than 1% are no longer considered narcotic drugs under the Federal Law on Narcotic Drugs and Psychotropic Substances.

The production, sale and trade of cannabis with a THC content of less than 1% is thus permitted in Switzerland.

As a tobacco substitute, dried cannabis flowers are subject to the provisions of the Ordinance on Tobacco Products and Products Containing Tobacco Substitutes for Smoking (OTab).

These products must be registered with the Federal Office of Public Health (FOPH), which verifies, among other things, on the basis of analyses that the THC content is below the 1% threshold.

To date, CBD is not considered to be a medicinal product and it is prohibited to claim any possible therapeutic effects or merits.